Entity
  • Crossject

    Created in 2001
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    1,163 5,194
  • Activities

  • Technologies

  • Entity types

  • Location

    6 Rue Pauline Kergomard, 21000 Dijon, France

    Dijon

    France

  • Employees

    Scale: 51-200

    Estimated: 94

  • Engaged corporates

    20
    8 4
  • Added in Motherbase

    3 years, 3 months ago
Description
  • Value proposition

    Expert des médicaments d'urgence auto-administrés

    Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.


    Injection sans aiguile and Traitements d'urgence

  • Original language

    Expert des médicaments d'urgence auto-administrés

    Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

  • Crossject | Needle free injection | ZENEO®

    Crossject developed ZENEO®, a world-leading needle-free injection platform, designed to improve patients’ safety and comfort and to enable a better observance of treatments. Needleless free injection of medicinal solution.

  • https://www.crossject.com/en
Corporate interactions BETA
Corporate TypeTweets Articles
J.P. Morgan J.P. Morgan
Bank
Other

10 Jan 2024


Eurofins Scientifique
Eurofins Scientifique
Biotechnology, Biotechnology Research
Eurofins Scientifique
Biotechnology, Biotechnology Research
Other

23 Jul 2024


Business France
Business France
National and local authorities, Government Administration
Business France
National and local authorities, Government Administration
Other

17 May 2024


ANSM Agence nationale de sécurité du médicament et des produits de santé ANSM Agence nationale de sécurité du médicament et des produits de santé
Other

7 Sep 2023


Syneos Health
Syneos Health
Pharmaceutical, Biotechnology Research
Syneos Health
Pharmaceutical, Biotechnology Research
Other

30 Sep 2024


Gouvernement Gouvernement
Other

4 Oct 2023


MEDEF
MEDEF
NGO, Think Tank, Civic and Social Organizations
MEDEF
NGO, Think Tank, Civic and Social Organizations
Other

27 Sep 2023


La Tribune
La Tribune
Media, Newspapers
La Tribune
Media, Newspapers
Other

1 Sep 2023


Leem
Leem
Startup accelerator & VC, Pharmaceutical Manufacturing
Leem
Startup accelerator & VC, Pharmaceutical Manufacturing
Other

13 Mar 2024


SAYENS
SAYENS
Research, Startup accelerator & VC, Research Services
SAYENS
Research, Startup accelerator & VC, Research Services
Other

25 Mar 2023


Similar entities
Loading...
Loading...
Social network dynamics